Incyte (INCY) Receivables (2010 - 2026)
Incyte posted quarterly Receivables of $1.1 billion for Q1 2026, up 27.74% year-on-year from $823.1 million in Q1 2025, and up 2.64% on a QoQ basis from $1.0 billion in Q4 2025.
Incyte (INCY) has 17 years of Receivables data on file, last reported at $1.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Receivables rose 27.74% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 27.74% YoY), and the FY2025 full-year result was $1.0 billion, up 20.07% from the prior year.
- Receivables for Q1 2026 stood at $1.1 billion, up from $1.0 billion in the prior quarter.
- Across five years, Receivables topped out at $1.1 billion in Q1 2026 and bottomed at $562.3 million in Q1 2022.
- The 5-year median for Receivables is $743.6 million (2023), against an average of $759.1 million.
- The widest annual swing landed in 2022, when Receivables soared 55.87%; it then slipped 6.59% in 2023.
- A 5-year view of Receivables shows it stood at $644.9 million in 2022, then grew by 15.3% to $743.6 million in 2023, then gained by 14.74% to $853.2 million in 2024, then increased by 20.07% to $1.0 billion in 2025, then rose by 2.64% to $1.1 billion in 2026.
- The last three Receivables figures came in at $1.1 billion (Q1 2026), $1.0 billion (Q4 2025), and $895.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 1.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.05 Bn |
| Dec 31, 2025 | 1.02 Bn |
| Sep 30, 2025 | 895.89 Mn |
| Jun 30, 2025 | 842.89 Mn |
| Mar 31, 2025 | 823.13 Mn |
| Dec 31, 2024 | 853.15 Mn |
| Sep 30, 2024 | 758.45 Mn |
| Jun 30, 2024 | 739.05 Mn |
| Mar 31, 2024 | 745.53 Mn |
| Dec 31, 2023 | 743.56 Mn |
| Sep 30, 2023 | 657.26 Mn |
| Jun 30, 2023 | 637.99 Mn |
| Mar 31, 2023 | 623.79 Mn |
| Dec 31, 2022 | 644.88 Mn |
| Sep 30, 2022 | 618.19 Mn |
| Jun 30, 2022 | 682.97 Mn |
| Mar 31, 2022 | 562.34 Mn |
| Dec 31, 2021 | 616.30 Mn |
| Sep 30, 2021 | 516.69 Mn |
| Jun 30, 2021 | 438.17 Mn |
| Mar 31, 2021 | 397.36 Mn |
| Dec 31, 2020 | 481.99 Mn |
| Sep 30, 2020 | 356.18 Mn |
| Jun 30, 2020 | 420.25 Mn |
| Mar 31, 2020 | 351.52 Mn |
| Dec 31, 2019 | 308.81 Mn |
| Jun 30, 2019 | 302.68 Mn |
| Mar 31, 2019 | 244.08 Mn |
| Dec 31, 2018 | 307.60 Mn |
| Sep 30, 2018 | 247.74 Mn |
| Jun 30, 2018 | 316.31 Mn |
| Mar 31, 2018 | 220.19 Mn |
| Dec 31, 2017 | 266.30 Mn |
| Sep 30, 2017 | 198.35 Mn |
| Jun 30, 2017 | 169.52 Mn |
| Mar 31, 2017 | 244.98 Mn |
| Dec 31, 2016 | 148.76 Mn |
| Sep 30, 2016 | 131.52 Mn |
| Jun 30, 2016 | 129.49 Mn |
| Mar 31, 2016 | 101.28 Mn |
| Dec 31, 2015 | 114.45 Mn |
| Sep 30, 2015 | 86.97 Mn |
| Jun 30, 2015 | 75.12 Mn |
| Mar 31, 2015 | 69.60 Mn |
| Dec 31, 2014 | 57.93 Mn |
| Sep 30, 2014 | 109.60 Mn |
| Jun 30, 2014 | 47.21 Mn |
| Mar 31, 2014 | 46.39 Mn |
| Dec 31, 2013 | 35.37 Mn |
| Sep 30, 2013 | 33.20 Mn |
| Jun 30, 2013 | 27.52 Mn |
| Mar 31, 2013 | 28.04 Mn |
| Dec 31, 2012 | 70.95 Mn |
| Sep 30, 2012 | 16.54 Mn |
| Jun 30, 2012 | 13.84 Mn |
| Mar 31, 2012 | 13.01 Mn |
| Dec 31, 2011 | 25.42 Mn |
| Sep 30, 2011 | 2.46 Mn |
| Jun 30, 2011 | 2.38 Mn |
| Mar 31, 2011 | 16.58 Mn |
| Dec 31, 2010 | 5.70 Mn |